Centessa Pharmaceuticals plc (CNTA) Financial Statements (2024 and earlier)

Company Profile

Business Address 3RD FLOOR
ALTRINCHAM, CHESHIRE, WA14 2DT
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments393,644,000595,082,000
Cash and cash equivalents393,644,000595,082,000
Short-term investments  
Prepaid expense2,788,0004,661,000
Other current assets3,271,000993,000
Other undisclosed current assets38,044,00028,038,000
Total current assets:437,747,000628,774,000
Noncurrent Assets
Operating lease, right-of-use asset  
Property, plant and equipment1,168,000162,000
Deferred income tax assets  
Other noncurrent assets5,392,000699,000
Total noncurrent assets:6,560,000861,000
TOTAL ASSETS:444,307,000629,635,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities38,338,00024,638,000
Accounts payable13,836,0008,065,000
Accrued liabilities24,502,00016,573,000
Total current liabilities:38,338,00024,638,000
Noncurrent Liabilities
Long-term debt and lease obligation69,800,00075,700,000
Long-term debt, excluding current maturities69,800,00075,700,000
Liabilities, other than long-term debt 43,000
Other liabilities  43,000
Operating lease, liability  
Other undisclosed noncurrent liabilities  37,700,000
Total noncurrent liabilities:69,800,000113,443,000
Total liabilities:108,138,000138,081,000
Equity
Equity, attributable to parent336,169,000491,554,000
Common stock265,000252,000
Additional paid in capital939,261,000876,267,000
Accumulated other comprehensive income (loss)(1,497,000)688,000
Accumulated deficit(601,860,000)(385,653,000)
Total equity:336,169,000491,554,000
TOTAL LIABILITIES AND EQUITY:444,307,000629,635,000

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Operating expenses(210,283,000)(359,002,000)
Other undisclosed operating loss (1,980,000)(15,082,000)
Operating loss:(212,263,000)(374,084,000)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
2,342,000(4,370,000)
Interest and debt expense  
Loss from continuing operations before equity method investments, income taxes:(209,921,000)(378,454,000)
Other undisclosed income (loss) from continuing operations before income taxes(7,033,000)(2,503,000)
Loss from continuing operations before income taxes:(216,954,000)(380,957,000)
Income tax expense (benefit)747,000(114,000)
Loss from continuing operations:(216,207,000)(381,071,000)
Loss before gain (loss) on sale of properties:(381,071,000)
Net loss available to common stockholders, diluted:(216,207,000)(381,071,000)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(216,207,000)(381,071,000)
Other comprehensive loss  
Comprehensive loss:(216,207,000)(381,071,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2,185,000)778,000
Comprehensive loss, net of tax, attributable to parent:(218,392,000)(380,293,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: